JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

JNJ

228.31

-0.64%↓

UNH

370.71

+0.2%↑

TMO

470.73

-1.19%↓

ISRG

459.72

+1.12%↑

ABT

89.85

-0.84%↓

Search

Twist Bioscience Corp

Open

SectorHealthcare

59.87 1.53

Overview

Share price change

24h

Current

Min

57.53

Max

60.64

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-3.35% downside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

1.1B

3.7B

Previous open

58.34

Previous close

59.87

News Sentiment

By Acuity

50%

50%

186 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

30 Apr 2026, 23:08 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 Apr 2026, 23:07 UTC

Earnings

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 Apr 2026, 22:20 UTC

Earnings

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 Apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 Apr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30 Apr 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 Apr 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 Apr 2026, 23:22 UTC

Earnings

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 Apr 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 Apr 2026, 22:52 UTC

Earnings

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 Apr 2026, 22:33 UTC

Earnings

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 Apr 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 Apr 2026, 22:32 UTC

Earnings

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 Apr 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 Apr 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 Apr 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 Apr 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 Apr 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 Apr 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30 Apr 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 Apr 2026, 22:05 UTC

Earnings

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 Apr 2026, 21:57 UTC

Earnings

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 Apr 2026, 21:56 UTC

Earnings

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 Apr 2026, 21:56 UTC

Earnings

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 Apr 2026, 21:55 UTC

Earnings

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 Apr 2026, 21:54 UTC

Earnings

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 Apr 2026, 21:54 UTC

Earnings

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 Apr 2026, 21:53 UTC

Earnings

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 Apr 2026, 21:49 UTC

Earnings

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 Apr 2026, 21:49 UTC

Earnings

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

-3.35% downside

12 Months Forecast

Average 54.8 USD  -3.35%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

186 / 347 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat